Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Private Trust Co. NA

Private Trust Co. NA cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 222 shares of the biopharmaceutical company’s stock after selling 50 shares during the period. Private Trust Co. NA’s holdings in Regeneron Pharmaceuticals were worth $233,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Brown Lisle Cummings Inc. grew its position in shares of Regeneron Pharmaceuticals by 18.2% in the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 10 shares during the period. Sachetta LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the last quarter. Adirondack Trust Co. lifted its holdings in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 10 shares during the period. UMB Bank n.a. boosted its position in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the last quarter. Finally, Western Financial Corp CA grew its holdings in Regeneron Pharmaceuticals by 0.7% in the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock valued at $1,912,000 after purchasing an additional 12 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on REGN shares. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Evercore ISI cut their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Oppenheimer decreased their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,107.29.

Regeneron Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ:REGN opened at $754.87 on Friday. The firm has a market cap of $82.95 billion, a PE ratio of 18.68, a price-to-earnings-growth ratio of 2.89 and a beta of 0.15. The company has a fifty day simple moving average of $913.54 and a 200 day simple moving average of $1,020.69. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $735.95 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.